Monument Capital Management Grows Stake in Johnson & Johnson $JNJ

Monument Capital Management raised its stake in Johnson & Johnson (NYSE:JNJ) by 44.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,012 shares of the company’s stock after acquiring an additional 1,847 shares during the period. Monument Capital Management’s holdings in Johnson & Johnson were worth $918,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of JNJ. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth $35,000. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at $48,000. Finally, von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at $49,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.2%

JNJ stock opened at $190.66 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The business’s 50-day moving average is $178.48 and its two-hundred day moving average is $163.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market cap of $459.16 billion, a price-to-earnings ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. UBS Group set a $198.00 price target on Johnson & Johnson in a report on Friday, October 3rd. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday. Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.